Professor Ric Price, affiliated with our OUCRU unit, tells us of his research on surveillance, diagnostics and treatments for Plasmodium vivax malaria Vivax malaria used to be considered benign but is now recognised as an important cause of morbidity and mortality. Resistance to chloroquine (given to treat the parasite blood stage) is growing and ACT (artemisinin-based combination therapy) is becoming common treatment for vivax malaria. New drugs and better public health strategies can help elimination targets, anticipated for 2030.